The Kremlin on Thursday said there were technological differences between Moscow and the European Medicines Agency (EMA) regarding the completeness of paperwork submitted for the certification of Russia’s Sputnik V vaccine.

The EU drug regulator is unlikely to decide whether to approve Sputnik V until at least the first quarter of 2022 because some data needed for the review was still missing, a source with knowledge of the matter told Reuters.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)